Autor: |
Christine D. Palmer, Ciaran D. Scallan, Lauren D. Kraemer Tardif, Melissa A. Kachura, Amy R. Rappaport, Daniel O. Koralek, Alison Uriel, Leonid Gitlin, Joshua Klein, Matthew J. Davis, Harshni Venkatraman, Meghan G. Hart, Jason R. Jaroslavsky, Sonia Kounlavouth, Martina Marrali, Charmaine N. Nganje, Kyounghwa Bae, Tiffany Yan, Katharyn Leodones, Milana Egorova, Sue-Jean Hong, Jenchun Kuan, Silvia Grappi, Pedro Garbes, Karin Jooss, Andrew Ustianowski |
Jazyk: |
angličtina |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023) |
Druh dokumentu: |
article |
ISSN: |
2041-1723 |
DOI: |
10.1038/s41467-023-39053-9 |
Popis: |
Abstract SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, and severe complications can occur in older populations. Humoral immunity induced by authorized vaccines wanes within 6 months, and frequent boosts may only offer transient protection. GRT-R910 is an investigational self-amplifying mRNA (samRNA)-based SARS-CoV-2 vaccine delivering full-length Spike and selected conserved non-Spike T cell epitopes. This study reports interim analyses for a phase I open-label dose-escalation trial evaluating GRT-R910 in previously vaccinated healthy older adults (NCT05148962). Primary endpoints of safety and tolerability were assessed. Most solicited local and systemic adverse events (AEs) following GRT-R910 dosing were mild to moderate and transient, and no treatment-related serious AEs were observed. The secondary endpoint of immunogenicity was assessed via IgG binding assays, neutralization assays, interferon-gamma ELISpot, and intracellular cytokine staining. Neutralizing antibody titers against ancestral Spike and variants of concern were boosted or induced by GRT-R910 and, contrasting to authorized vaccines, persisted through at least 6 months after the booster dose. GRT-R910 increased and/or broadened functional Spike-specific T cell responses and primed functional T cell responses to conserved non-Spike epitopes. This study is limited due to small sample size, and additional data from ongoing studies will be required to corroborate these interim findings. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|